Table 2.
HIV-related characteristic of PLWH
| Epidemiology [n (%)] | |
| MSM | 3 (16.7) |
| MSW/WSM | 6 (33.3) |
| IDU | 6 (33.3) |
| Unknown | 3 (16.7) |
| Immunologic parameters [median (IQR)] | |
| CD4 T cell count nadir, cells/μL | 59 (12.5–331.3) |
| Current CD4 T cell count, cells/μL | 361.5 (210.3–653.5) |
| Current CD4/CD8 ratio | 0.4 (0.11–1.1) |
| Current CD4 T cell count [n (%)] | |
| <200 cells/μL | 4 (22.2) |
| 200–500 cells/μL | 7 (38.9) |
| >500 cells/μL | 7 (38.9) |
| Current plasma HIV-RNA [n (%)] | |
| Undetectable (<50 copies/mL) | 15 (83.3) |
| Detectable (50–100 copies/mL) | 1 (5.6) |
| Detectable (>105 copies/mL) | 2 (11.1) |
| Previous AIDS diagnosis [n (%)] | 5 (27.8) |
| Time from HIV diagnosis, years [median (IQR)] | 18 (6.25–34.5) |
| Current cART regimen [n (%)] | |
| INSTI-based | 9 (50) |
| PI-based | 3 (16.7) |
| INSTI+PI-based | 1 (5.6) |
| NNRTI-based | 3 (16.7) |
| None (cART-naïve) | 2 (11) |
MSM, men who have sex with men; MSW, men who have sex with women; WSM, women who have sex with men; IDU, injective drugs use; cART, combination antiretroviral therapy; INSTI, integrase strand transfer inhibitor; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor.